| Heart failure
Epaned vs Samsca
Side-by-side clinical, coverage, and cost comparison for heart failure.Deep comparison between: Epaned vs Samsca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSamsca has a higher rate of injection site reactions vs Epaned based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Samsca but not Epaned, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Epaned
Samsca
At A Glance
Oral
Once or twice daily
ACE inhibitor
Oral
Daily
Vasopressin V2-receptor antagonist
Indications
- Hypertensive disease
- Heart failure
- Ventricular Dysfunction, Left
- Hyponatremia
- Heart failure
- Inappropriate ADH Syndrome
Dosing
Hypertensive disease Adults: 5 mg once daily orally, titrated up to 40 mg daily; pediatric patients >1 month: 0.08 mg/kg (up to 5 mg) once daily; renal impairment (GFR <=30 mL/min) or dialysis: initial dose 2.5 mg daily.
Heart failure 2.5 mg twice daily orally, titrated up to 20 mg twice daily as tolerated; usually given in combination with diuretics and digitalis.
Ventricular Dysfunction, Left 2.5 mg twice daily orally, titrated up to 10 mg twice daily as tolerated.
Hyponatremia, Heart failure, Inappropriate ADH Syndrome Start at 15 mg once daily; titrate at intervals >=24 hours to 30 mg once daily, then to a maximum of 60 mg once daily as needed; initiate and re-initiate in a hospital; do not administer for more than 30 days.
Contraindications
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril), or within 36 hours of switching to or from sacubitril/valsartan
- Autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS
- Unable to sense or respond to thirst
- Hypovolemic hyponatremia
- Concomitant use of strong CYP3A inhibitors
- Anuria
- Hypersensitivity to tolvaptan or any components of the product
Adverse Reactions
Most common (>1%) Fatigue, orthostatic effects, asthenia, cough, rash; in heart failure patients: hypotension, dizziness.
Serious Angioedema, hypotension, hepatic failure, renal impairment, hyperkalemia, cardiac arrest, myocardial infarction, cerebrovascular accident, neutropenia, thrombocytopenia, bone marrow depression.
Postmarketing Pancreatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, eosinophilic pneumonitis, pulmonary infiltrates, gynecomastia.
Most common (>=5%) Thirst, dry mouth, asthenia, constipation, pollakiuria or polyuria, hyperglycemia
Serious Disseminated intravascular coagulation, intracardiac thrombus, ventricular fibrillation, ischemic colitis, diabetic ketoacidosis, rhabdomyolysis, cerebrovascular accident, pulmonary embolism, respiratory failure, deep vein thrombosis
Postmarketing Osmotic demyelination syndrome, hypernatremia, hypersensitivity reactions including anaphylactic shock and generalized rash
Pharmacology
ACE inhibitor; enalapril is hydrolyzed to enalaprilat, which inhibits angiotensin-converting enzyme, suppressing the renin-angiotensin-aldosterone system and thereby reducing plasma angiotensin II, vasopressor activity, and aldosterone secretion.
Tolvaptan is a selective vasopressin V2-receptor antagonist that blocks vasopressin's renal effect, promoting free water excretion (aquaresis) and raising serum sodium concentrations without significantly affecting urinary sodium or potassium excretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Epaned
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Samsca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Epaned
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Samsca
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Epaned
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Samsca
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Epaned.
$0
Otsuka Patient Assistance Foundation (OPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EpanedView full Epaned profile
SamscaView full Samsca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.